



# Jupiter Life Line Hospitals Limited

November 08, 2024

To,  
National Stock Exchange of India Ltd.  
Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai-400 051  
Symbol: **JLHL**

To,  
BSE Limited  
P.J. Towers,  
25<sup>th</sup> Floor, Dalal Street, Fort  
Mumbai 400 001  
Code: **543980**

**Subject: Investor Presentation for the quarter and half year ended September 30, 2024**

**Reference: Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter and half year ended September 30, 2024**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2024.

The same will be available on the website of the Company at [www.jupiterhospital.com](http://www.jupiterhospital.com).

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking You.

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti  
Company Secretary & Compliance Officer



**Bringing **care** into Healthcare.**

**Results Presentation**  
**Q2 & H1 FY25**



# Safe Harbour


---

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

## Dr. Ankit Thakker ED & CEO



*“We are pleased to report a 20.5% increase in total income, reaching Rs 612.8 crore in H1FY25, up from Rs 508.4 crore in H1FY24. EBITDA rose by 22.3% to Rs 141.9 crore, compared to Rs 116.1 crore in H1FY24, while PAT grew by 9.6% to Rs 96.1 crore in H1FY25, up from Rs 87.7 crore in H1FY24. This growth has been driven by strong operational performance across all three hospitals, reflected in higher occupancy rates and increased ARPOB.*

*In Q2FY25, we added 22 beds at our Pune hospital and are in the process of adding 75 new beds at our Indore hospital, which is expected to be operational by Q4FY25.*

*We are focused on expanding the Jupiter brand, enhancing management professionalism, and increasing our footprint. With this regards, the construction of our Dombivli hospital is progressing on schedule. For our Pune hospitals, we are in the advanced stages of obtaining the necessary regulatory approvals. With the addition of these two new facilities, our total bed capacity will increase to ~2,200 beds, and we are currently identifying another location to raise our total capacity to ~2,500 beds.*

*We have effectively leveraged our core strengths to drive growth, solidifying our position as a leading healthcare provider in Western India. By aligning these initiatives with our long-term growth vision, we have established a strong foundation for sustainable expansion and improved patient care.”*

**Patient First**

# Key Highlights of H1 FY25

**Total Income**  
**Rs. 612.8 Cr**

 **20.5 % YoY**

**EBITDA**

**Rs. 141.9 Cr**

 **22.3 % YoY**

**PAT**

**Rs. 96.1 Cr**

 **9.6 % YoY**

All three hospitals showed strong performance in H1 FY25, with overall volume and ARPOB increasing by 12% and 9% YoY, respectively

01

In the process of adding 75 beds in Indore Hospital, which is expected to be operational by Q4FY25

02

In Q2 FY25, 22 beds were added in Pune

03

Construction of Dombivli Hospital is progressing well and is on track as per our target timelines

04


Our 2<sup>nd</sup> unit at Pune is in the advance stage of obtaining regulatory approvals

05


# H1 FY25 Performance Highlights

Rs in Crores


Total Income




EBITDA



PBT



PAT\*




■ IPD ■ OPD ■ Others


\*PAT for H1FY24 includes a benefit of deferred tax charge of Rs. 34.5 Crores

# H1 FY25 Operating Metrics


## Operational Bed Capacity<sup>(1)</sup>




## Average Occupancy Rate<sup>(2)</sup>




## IPD & OPD Volumes ('000)<sup>(3)</sup>




## ARPOB<sup>(4)</sup>



## ALOS (in Days)<sup>(5)</sup>



## Payor Mix




ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.


# Q2 FY25 Performance Highlights

Rs in Crores


Total Income




EBITDA



PBT






PAT



\*PAT for Q2FY24 includes a benefit of deferred tax charge of Rs. 4.1 Crores



# Operations at 3 Distinct Geographies

	Operating Beds <sup>(1)</sup>	Avg. Occupancy <sup>(2)</sup>	ARPOB <sup>(3)</sup>
 <p><b>Thane (2007)</b></p>	<b>377</b>	<b>72.0%</b>	<b>66,700</b>
 <p><b>Pune (2017)</b></p>	<b>375</b>	<b>67.0%</b>	<b>55,000</b>
 <p><b>Indore (2020)</b></p>	<b>231</b>	<b>59.0%</b>	<b>44,700</b>



**Thane, Pune, Indore are accredited for NABH Digital Health - Gold Standard**

As on 30<sup>th</sup> September'24 ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period)

# Consolidated Profit & Loss Statement

Profit and Loss (in Rs. Crs)	Q2FY25	Q2FY24	YoY	Q1FY25	QoQ	H1FY25	H1FY24	YoY	FY24
<b>Revenue from Operations</b>	<b>320.0</b>	<b>260.8</b>	<b>22.7%</b>	<b>284.5</b>	<b>12.5%</b>	<b>604.5</b>	<b>501.5</b>	<b>20.5%</b>	<b>1,059.8</b>
Other Income - Operational	4.2	3.4		4.1		8.3	6.9		13.6
<b>Total Income</b>	<b>324.2</b>	<b>264.2</b>	<b>22.7%</b>	<b>288.6</b>	<b>12.3%</b>	<b>612.8</b>	<b>508.4</b>	<b>20.5%</b>	<b>1,073.4</b>
Cost of Goods Sold	60.0	46.2		50.2		110.2	88.6		189.5
<b>Gross Profit</b>	<b>264.2</b>	<b>218.0</b>	<b>21.2%</b>	<b>238.4</b>	<b>10.8%</b>	<b>502.6</b>	<b>419.9</b>	<b>19.7%</b>	<b>884.0</b>
<b>Gross Profit Margin</b>	<b>81.5%</b>	<b>82.5%</b>		<b>82.6%</b>		<b>82.0%</b>	<b>82.6%</b>		<b>82.3%</b>
Employee Cost	53.9	43.3		51.3		105.2	88.4		189.9
Professional Fees	79.8	69.7		72.2		152.0	131.6		271.4
Other Expenses	53.9	43.0		49.6		103.5	83.8		180.6
<b>EBITDA</b>	<b>76.6</b>	<b>62.0</b>	<b>23.5%</b>	<b>65.3</b>	<b>17.3%</b>	<b>141.9</b>	<b>116.1</b>	<b>22.3%</b>	<b>242.1</b>
<b>EBITDA Margin</b>	<b>23.6%</b>	<b>23.5%</b>		<b>22.6%</b>		<b>23.2%</b>	<b>22.8%</b>		<b>22.6%</b>
Depreciation	14.4	10.6		11.0		25.4	21.3		42.4
<b>EBIT</b>	<b>62.2</b>	<b>51.4</b>	<b>21.0%</b>	<b>54.3</b>	<b>14.6%</b>	<b>116.5</b>	<b>94.7</b>	<b>23.0%</b>	<b>199.7</b>
<b>EBIT Margin</b>	<b>19.2%</b>	<b>19.5%</b>		<b>18.8%</b>		<b>19.0%</b>	<b>18.6%</b>		<b>18.6%</b>
Other Income - Finance	7.8	3.0		6.9		14.7	6.9		22.0
Finance Cost	1.1	12.2		1.1		2.2	24.4		26.3
Exceptional Item Gain / (Loss)	0.0	0.8		0.0		0.0	-2.1		0.0
<b>PBT</b>	<b>68.9</b>	<b>41.4</b>	<b>66.6%</b>	<b>60.1</b>	<b>14.6%</b>	<b>129.1</b>	<b>75.1</b>	<b>71.8%</b>	<b>195.4</b>
<b>PBT Margin</b>	<b>21.3%</b>	<b>15.7%</b>		<b>20.8%</b>		<b>21.1%</b>	<b>14.8%</b>		<b>18.2%</b>
Tax	17.4	7.7		15.5		32.9	-12.5		18.8
<b>PAT<sup>#</sup></b>	<b>51.5</b>	<b>33.7</b>	<b>52.9%</b>	<b>44.6</b>	<b>15.5%</b>	<b>96.1</b>	<b>87.7</b>	<b>9.6%</b>	<b>176.6</b>
<b>PAT Margin</b>	<b>15.9%</b>	<b>12.8%</b>		<b>15.5%</b>		<b>15.7%</b>	<b>17.2%</b>		<b>16.5%</b>
Basic EPS	7.86*	5.67*		6.8*		15.60*	14.66*		28.65

#Includes benefit of deferred tax charge  
-Q1FY24 Rs. 30.4 Crores, Q2FY24 Rs 4.1 crores, FY24 Rs 34.5 crores

\* Not Annualised

# Consolidated Balance Sheet

Equity & Liabilities (in Rs. Crs)	Sep-24	Mar-24
<b>Total Equity</b>	<b>1,258.3</b>	<b>1,168.7</b>
Share Capital	65.6	65.6
Other Equity	1,192.8	1,103.5
Minority Interest	-0.1	-0.3
<b>Non-Current Liabilities</b>	<b>7.5</b>	<b>6.8</b>
<b>Financial Liabilities</b>		
Deferred Tax Liabilities	3.9	3.7
Other non current liabilities	3.5	3.1
<b>Current Liabilities</b>	<b>128.7</b>	<b>105.8</b>
<b>Financial Liabilities</b>		
(i) Trade Payables	51.4	62.2
Other Current Liabilities	20.7	16.7
Current tax liabilities (net)	10.8	2.2
Provisions	45.8	24.6
<b>Total Equity &amp; Liabilities</b>	<b>1,394.5</b>	<b>1,281.3</b>

Assets (in Rs. Crs)	Sep-24	Mar-24
<b>Non - Current Assets</b>	<b>964.6</b>	<b>871.6</b>
Property Plant & Equipments	748.2	715.5
CWIP	135.1	74.0
Other Intangible assets	3.0	2.1
<b>Financial Assets</b>		
Investments	0.1	0.1
Other Financial Assets	73.7	78.9
Other Non - Current Assets (Net)	4.5	0.9
<b>Current Assets</b>	<b>429.9</b>	<b>409.8</b>
Inventories	24.2	21.3
<b>Financial Assets</b>		
(i) Investments	83.3	16.9
(ii) Trade receivables	59.9	57.2
(iii) Cash and cash equivalentents	245.8	301.3
(iv) Loans	0.4	0.6
Other Current Assets	16.2	12.5
<b>Total Assets</b>	<b>1,394.5</b>	<b>1,281.3</b>

# Consolidated Cash Flow Statement

Profit and Loss (in Rs. Crs)	H1FY25	H1FY24
<b>Net Profit Before Tax</b>	<b>129.1</b>	<b>75.1</b>
Adjustments for: Non -Cash Items / Other Investment or Financial Items	20.3	44.2
<b>Operating profit before working capital changes</b>	<b>149.4</b>	<b>119.3</b>
Changes in working capital	1.8	-24.3
<b>Cash generated from Operations</b>	<b>151.2</b>	<b>95.1</b>
Direct taxes paid (net of refund)	-32.9	-22.1
<b>Net Cash from Operating Activities</b>	<b>118.2</b>	<b>73.0</b>
<b>Net Cash from Investing Activities</b>	<b>-165.3</b>	<b>-19.6</b>
<b>Net Cash from Financing Activities</b>	<b>-8.3</b>	<b>133.5</b>
<b>Net Decrease in Cash and Cash equivalents</b>	<b>-55.4</b>	<b>186.9</b>
Add: Cash & Cash equivalents at the beginning of the period	301.3	134.5
<b>Cash &amp; Cash equivalents at the end of the period</b>	<b>245.8</b>	<b>321.3</b>



**PATIENT FIRST**

**Jupiter Life Line Hospitals Limited**

CIN: L85100MH2002PLC137908

[investor.relations@jupiterhospital.com](mailto:investor.relations@jupiterhospital.com)

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

**Rahul Agarwal / Mandar Chavan**

[rahul.agarwal@sgapl.net](mailto:rahul.agarwal@sgapl.net) / [mandar.chavan@sgapl.net](mailto:mandar.chavan@sgapl.net)

+91 98214 38864 / +91 96993 82195